FDA Says Effexor XR Ad Overstates Antidepressant’s Second-Line Utility
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth no longer uses the journal ad targeted in warning letter, firm tells The Pink Sheet DAILY.